VASO Corp Files 2024 Proxy Statement

TL;DR

VASO Corp dropped its 2024 proxy statement, shareholders vote soon.

AI Summary

VASO Corp filed its DEF 14A proxy statement on August 7, 2024, for the fiscal year ending December 31, 2024. The filing pertains to the company's annual meeting and related corporate governance matters. VASO Corp, formerly Vasomedical, Inc., is based in Plainview, NY, and operates in the electromedical apparatus industry.

Why It Matters

This filing provides shareholders with essential information regarding company operations, executive compensation, and voting matters, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial disclosures that would inherently increase risk.

Key Players & Entities

• VASO Corp (company) — Registrant
• Vasomedical, Inc. (company) — Former company name
• August 7, 2024 (date) — Filing date
• December 31, 2024 (date) — Fiscal year end
• Plainview, NY (location) — Company address

FAQ

Key Financial Figures

• $0.0001 — 1d;) of Class A Common Stock, par value $0.0001 per share, of Achari (the “Class
• $4.00 — Stock will have, among other things, a $4.00 per share minimum bid price upon the cl
• $0.40 — f our common stock would need to exceed $0.40 per share prior to the closing of the B
• $0.20 — f the Business Combination, for example $0.20 per share (in the event of a 1 -for-2 R
• $0.04 — k on the OTCQX ranged (i) from a low of $0.04 to a high of $0.22 in 2022 and (ii) fro
• $0.22 — ed (i) from a low of $0.04 to a high of $0.22 in 2022 and (ii) from a low of $0.16 to
• $0.16 — of $0.22 in 2022 and (ii) from a low of $0.16 to a high of $0.37 in 2023. Although th
• $0.37 — d (ii) from a low of $0.16 to a high of $0.37 in 2023. Although the closing price of
• $0.23 — e closing price of our common stock was $0.23 per share on July 11, 2024, we believe
• $0.001 — s of July 15, 2024, with a par value of $0.001 per share, and 1,000,000 shares
• $0.01 — of preferred stock with a par value of $0.01 per share, none of which are issued or

Filing Documents

• ea0201069-04.htm (DEF 14A) — 36830KB
• tflowchart_001.jpg (GRAPHIC) — 194KB
• tflowchart_002.jpg (GRAPHIC) — 454KB
• tflowchart_003.jpg (GRAPHIC) — 451KB
• triver_sig.jpg (GRAPHIC) — 53KB
• 0001213900-24-065802.txt ( ) — 38418KB

From the Filing

DEF 14A 1 ea0201069-04.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ SCHEDULE 14A ________________ Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant   ☒ Filed by a Party other than the Registrant   ☐ Check the appropriate box: ☐   Preliminary Proxy Statement ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2)) ☒   Definitive Proxy Statement ☐   Definitive Additional Materials ☐   Soliciting Material under §240.14a -12 VASO CORPORATION (Name of Registrant as Specified In Its Charter) ___________________________________________________________ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒   No fee required ☐   Fee paid previously with preliminary materials ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0 -11   Table of Contents Vaso Corporation 137 Commercial Street, Suite 200 Plainview, New York 11803 Dear Stockholders: You are cordially invited to attend the special meeting in lieu of the 2023 annual meeting of the stockholders of Vaso Corporation (“Vaso” or the “Company”) to be held at the Lever House, 390 Park Avenue, Third Floor, New York, NY 10022 on August 26, 2024 beginning at 10:00 A.M. EDT. Vaso is a Delaware corporation that operates in three distinct business segments in the healthcare equipment and information technology industries. Holders of Vaso common stock will be asked to approve, among other things, the Business Combination Agreement, dated as of December 6, 2023 by and among Achari Ventures Holdings Corp. I, a Delaware corporation (“Achari”), Vaso Corporation, a Delaware corporation (“Vaso”), and Achari Merger Sub, Inc., a Delaware corporation and wholly -owned  subsidiary of Achari (the “Merger Sub”) (as amended from time to time, the “Business Combination Agreement”), pursuant to which the Merger Sub will merge (the “Merger”) with and into Vaso, with Vaso surviving the merger (the “transactions contemplated by the Business Combination Agreement”), including, without limitation, the Merger, the “Business Combination”). As a result, Vaso will become a wholly -owned  subsidiary of Achari following the Business Combination (“New Vaso”). The former holders of the capital stock of Vaso will be entitled to receive up to an aggregate of 17,600,000 shares (such amount of shares assumes that a reverse stock split (the “Reverse Stock Split”) of the outstanding shares of Achari common stock at a ratio in the range of 1 -for-1 to 2 -for-1 , with the decision to effectuate such Reverse Stock Split and the ratio of such Reverse Stock Split to be determined at the discretion of the Achari Board does not occur; for further information with respect to the Reverse Stock Split and certain conditions precedent to the Reverse Stock Split occurring, see the Questions and Answers entitled “ What is the Reverse Stock Split? ” and “ Why is Achari proposing the Achari Reverse Stock Split Proposal? ”) of Class A Common Stock, par value $0.0001 per share, of Achari (the “Class A Common Stock”) of New Vaso in exchange for all of the outstanding shares of Vaso capital stock . In certain instances herein, we have assumed that the Reverse Stock Split does not occur because the Reverse Stock Split will only occur if the trading price of our common stock does not meet applicable price thresholds set by Nasdaq in connection with Nasdaq’s initial listing standards. As part of their initial listing standards, Nasdaq requires that the Class A Common Stock will have, among other things, a $4.00 per share minimum bid price upon the closing of the Business Combination. Such $4.00 per share minimum bid price takes into account the Exchange Ratio included in the Business Combination Agreement of 0.0998 and the pre -closing per share bid price of our common stock. With such an Exchange Ratio, the closing bid price of our common stock would need to exceed $0.40 per share prior to the closing of the Business Combination in order to satisfy Nasdaq’s initial listing standards. However, if the Reverse Stock Split were to occur, the Exchange Ratio would be proportionally adjusted to reflect such Reverse Stock Split, and the closing bid pri

View Full Filing

View this DEF 14A filing on SEC EDGAR